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Abstract
Objective To investigate the use of a novel study design in analysis of
bilateral elbow pain.
Design N of 1, two contemporary arm, open label, randomised controlled
clinical trial.
Setting A clinical epidemiologist at a university hospital in Pavia, Italy.
Participants Two elbows with epicondylitis.
Interventions Autologous platelet lysate versus “wait and see” strategy.
Main outcome measures Visual analogue scale for pain on elbow
extension and resisted wrist extension.
Results Over six months’ follow-up, the patient experienced bilateral
improvement in pain, but higher in the treated arm, with a drop in visual
analogue scale for pain from 28 to 4 for right (control) arm (drop of 24
points) and from 67 to 10.5 for left (treated) arm (drop of 56.5 points).
Conclusions Platelet lysate might (or might not) work. Competing
interests and lack of blinding might be relevant issues in the interpretation
of trial results. However, the new study design can be applied to a
number of conditions such as bilateral sport or trauma injuries, bilateral
otitis, or any condition affecting chiral organs or limbs.
Introduction
The history of research is replete with examples of researchers
experimenting on themselves,
1 but, to our knowledge, this is
the first instance where a clinical epidemiologist has drawn up
a new study design, performed the trial on herself, and reported
the results.
Patient and methods
History
LS, a former infectious disease specialist now a clinical
epidemiologist, became the mother of twins in 2007 at the age
of 37 years. Two years later, besides representing a
quasi-experimentalstudyoftheresidualeffectsofchronicsleep
loss on human performance
2 3 and of memory impairment by
sleep disruption,
4 she had her third relapse of bilateral
epicondylitis in less than two years.
5
After unsuccessful treatments with topical and systemic
non-steroidal anti-inflammatory drugs, arm straps, icing,
ultrasound therapy, and laser therapy,
6 these episodes were
treated with intra-articular corticosteroid injections with high
efficacy in the short term.
7 As a result, severe skin atrophy was
present bilaterally at the time the study started.
Her blood biochemistry, C reactive protein concentration,
erythrocyte sedimentation rate, and tests for rheumatoid factor
and autoantibodies were normal. Ultrasound examination
revealedbilateralactiveinflammationandminuteintratendinous
calcifications.Magneticresonanceimagingconfirmedbilateral
thickening of the common extensor tendon, with surrounding
soft tissue oedema and focal oedema areas in the bone of the
radial head and of the lateral epicondyle of the humerus (fig
1⇓).
As symptoms reached Nirschl phase VI to VII, she was about
tostartacourseofantidepressanttherapy,whenshehadasurge
of professional pride. Conducting a systematic review of the
literature,shefoundmanyrelevantpapersondozensofpossible
treatments and focused on a promising report of successful
treatment with platelet rich plasma
8 (also expected to reverse
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Research
RESEARCHthe deleterious effect of previous steroid injections
9). She
identified an ongoing clinical trial,
10 wrote to the researchers,
andwasreferredtoapublishedabstractindicating80%success
at one year.
Study design
She designed an n of 1, two contemporary arm, open label,
randomised controlled trial in which the treatment arm would
coincide with the treated arm.
11-14
ForarmA(intheepidemiologicalsense),treatmentwithplatelet
lysate injections (2.5 ml injection every four weeks for three
times) was chosen. Platelet lysate is a solution of bioactive
molecules obtained by platelet destruction by freeze-thawing.
15
The choice of the comparator was a challenge. The researcher,
having reviewed the literature, found numerous alternatives:
acupuncture, shock wave therapy, topical glyceryl trinitrate,
transcutaneous electrical nerve stimulation (TENS),
tecartherapy, orthotics, physiotherapy, botulinum injections,
complete immobilisation, long term arm straps, and surgery.
6
Ultimately,sheselecteda“waitandsee”strategyforthecontrol
arm.
Because of the extremely painful nature of the treatment arm
(in the epidemiological sense) (local anaesthetics were not
allowed, to avoid dilution of the active drug and to limit the
injection volume), blinding and masking was not accepted by
thepatient.Infact,aplaceboeffectcouldnotbeetymologically
anticipated, and injection of any amount of inactive liquid into
an inextensible and inflamed tendon is likely to be
unacceptable.
16
Randomisation of arms (in the anatomical sense) was deemed
appropriate since no residual and differential effect of previous
localtreatmentswashypothesised.Randomisationwasachieved
by the flipping of a 1 euro coin. No drugs interfering with
platelet functions were allowed, nor systemic support in the
form of domestic help.
Since the effects on elbows need to be proved,
17 outcome
measures for measures were based on a visual analogue scale
for pain on elbow extension and resisted wrist extension
(primary),onthepatientratedtenniselbowevaluation(PRTEE)
scale,
18 and other pain and functional scales, and assessed at
baseline and at one, three, and six months. All were primary
end points to the patient.
Informed consent and other ethical issues
The researchers were not allowed to seek formal ethical
committee approval
19 because of an irresolvable conflict of
interest (rather a national trait in Italy). Since the patient wished
toavoiddelaysintreatment,
20 21theydidnotinsistandproceeded
with the usual informed consent practices.
22
Results
Platelet lysate was injected intratendinously by CP on 19
February,11March,and21April2010understerileconditions
(LS, being an infectious disease specialist, particularly stressed
the need for hand washing). At the time of first injection (12
months from last corticosteroid injection), skin atrophy had
almost completely resolved.
Baseline and follow-up measures are reported in the table⇓ and
fig 2⇓. At the one year follow-up, the patient reports having
built a piece of furniture by Ikea almost by herself.
Discussion
The relevance of n of 1 trials in evidence based medicine are
increasingly recognised.
25 Criteria for determining whether an
n of 1 trial is appropriate are well established,
14 26 27 and,
according to these, our trial should not have been conducted in
viewofhavingtoreply“No”tothequestion“Willthetreatment,
if effective, be continued long term?”
However, according to the well known principle “There are
more things in heaven and earth than are dreamt of in your
clinicalepidemiologyhandbook,”
28wehavecreatedanewstudy
design. In this setting, even with cure as the final objective and
without repeated periods of treatment, “control-ateral” arm (in
the anatomical sense) provides the necessary “control” arm (in
the epidemiological sense), thanks to a local treatment being
available (that is, with no systemic or controlateral effect
anticipated), whereas n of 1 trials have otherwise been used
only for systemic treatments.
This new study design could be applied to a number of
conditions such as bilateral sport or trauma injuries, bilateral
otitis media, bilateral conjunctivitis (indeed, any condition
involving chiral organs or limbs).
Study limitations
Many would agree that n of 1 trials do not represent research,
but (only) the highest standards of establishing benefits and
harmsoftherapyinanindividual.
11 29Ontheotherhand,aswith
any single subject research, the generalisability of n of 1 trials
is enhanced with within patient (ABA or ABAB designs)
replication or between patient replication. This was made
explicitbyotherresearcherssomeyearsago—“Deathfordeath,
haste still pays haste, and leisure answers leisure; like doth quit
like, and measure still for measure.”
30 Hopefully, it will not be
possible to replicate the trial in this patient. If other patients
withbilateralepicondylitispresent,othertrialswillbeconducted
(we will be glad to provide the research protocol), and results
might be combined.
31
A considerable source of bias is the fact that the patient is a
researcheraswell.Singleselfexperimentshavebeencategorised
as self indulgence or abuse, and trivial interventions
masquerading as research studies as a source of amusement.
19
In the present study, the intervention was by no means trivial,
requiring high scientific, clinical, and technical expertise from
theinvestigators,andhighmotivationfromthepatient.Besides,
experimental units were two (right and left elbows), and the
patient-researcher was at the same time self indulgent (right
elbow)andselfabusing(leftelbow).Finally,shewasinnoway
amused by the clinical situation.
In addition, the patient was not blind to the treated arm, and
objective measures were not used. However, the patient was
carefully instructed to forget which arm was given which
treatment, was sent electronic reminders of the scheduled
assessmentstoavoidmissingdata,and,incasesheforgotdespite
all this,
4 the researcher filled in the questionnaires herself.
Conclusions
At end of the trial, both arms were almost pain-free, but the
drop in pain in the treated arm was greater than in the control
arm. This allows several different conclusions to be drawn on
efficacy of platelet lysate in chronic refractory epicondylitis:
1)Itiseffective,sincedropinpainwassteeperinthetreated
arm
2)Itisnoteffective,andimprovementwasduetothenatural
course of lateral epicondylitis
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RESEARCH3) It is effective, and the parallel improvement in the
untreatedarmcouldhavebeenmediatedbytheimprovement
in the treated arm, by allowing a more equal distribution of
workload
4) Both arms benefited from participation into a clinical
trial
32
5) More studies are needed.
Contributors: LS drafted the study protocol, submitted (unsuccessfully)
the study protocol to the ethics committee, underwent the experimental
treatment, collected the data, performed the statistical analyses, and
drafted the report. She is the guarantor. CDF drew blood from LS,
prepared the lysate and, more importantly, held the patient’s hand during
the injections. CP participated in drafting the study protocol and
preparation of lysate injections. CFP performed the injections (without
anaesthesia, a reason why his authorship should not be allowed). DC
performed radiological examinations. VS led the systematic review of
the literature and retrieved even the most improbable reports from the
most elusive medical and lay journals. CT had the original idea for the
study, supervised data collection and clinical assessments, checked
data quality control, and performed the randomisation.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare that (1) LS is the
patient-researcher, (2) all the others are her friends and colleagues and
all have personal interests relevant to the present work since they were
definitely fed up with LS’s complaints about her pain and disability related
scores in QoL questionnaires, (3) no support from any organisation for
the submitted work; no financial relationships with any organisations
that might have an interest in the submitted work in the previous three
years, no other relationships or activities that could appear to have
influenced the submitted work.
1 Altman LK. Who goes first? The story of self-experimentation in medicine . University of
California Press, 1986.
2 Cohen DA, Wang W, Wyatt JK, Kronauer RE, Dijk D-J, Czeisler CA, et al. Uncovering
residual effects of chronic sleep loss on human performance. Sci Transl Med 2010;2:14ra3.
3 Axelsson J, Sundelin T, Ingre M, Van Someren EJ, Olsson A, Lekander M. Beauty sleep:
experimental study on the perceived health and attractiveness of sleep deprived people.
BMJ 2010;341:c6614.
4 Rolls A, Colas D, Adamantidis A, Carter M, Lanre-Amos T, Heller HC, et al. Optogenetic
disruption of sleep continuity impairs memory consolidation. Proc Natl Acad Sci USA
2011;108:13305-10.
5 Faro F, Wolf JM. Lateral epicondylitis: review and current concepts. J Hand Surg Am
2007;32:1271-9.
6 Mahaffey P. Tennis elbow: there is no proved treatment. BMJ 2009;339:b5325.
7 O’Connor RF. Tennis elbow: injecting steroids is not good. BMJ 2009;339:b5319.
8 Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich
plasma. Am J Sports Med 2006;34:1774-8.
9 Wong MW, Tang YY, Lee SK, Fu BS, Chan BP, Chan CK. Effect of dexamethasone on
cultured human tenocytes and its reversibility by platelet-derived growth factor. J Bone
Joint Surg Am 2003;85-A:1914-20.
10 Gosens T, Peerbooms JC, van Laar W, den Oudsten BL. Ongoing positive effect of
platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind
randomized controlled trial with 2-year follow-up. Am J Sports Med 2011;39:1200-8.
11 Irwig L, Glasziou P, March L. Ethics of n-of-1 trials. Lancet 1995;345:469.
12 Keller JL, Guyatt GH, Roberts RS, Adachi JD, Rosenbloom D. An N of 1 service: applying
the scientific method in clinical practice. Scand J Gastroenterol Suppl 1988;147:22-9.
13 Tsapas A, Matthews DR. Using N-of-1 trials in evidence-based clinical practice. JAMA
2009;301:1022-3.
14 Tate RL, McDonald S, Perdices M, Togher L, Schultz R, Savage S. Rating the
methodological quality of single-subject designs and n-of-1 trials: introducing the
single-case experimental design (SCED) scale. Neuropsychol Rehabil 2008;18:385-401.
15 Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates:
from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF).
Trends Biotechnol 2009;27:158-67.
16 Treasure W. N of 1 trials. Placebos should be abandoned. BMJ 1996;313:427-8.
17 Shakespeare W. Measure for measure II. i. 535.
18 Rompe JD, Overend TJ, MacDermid JC. Validation of the patient-rated tennis elbow
evaluation questionnaire. J Hand Ther 2007;20:3-10.
19 Annas GJ. Self experimentation and the Nuremberg Code. BMJ 2010;341:c7103.
20 Chalmers I. What do I want from health research and researchers when I am a patient?
BMJ 1995;310:1315-8.
21 This week in the BMJ. New ethics committee regulations hinder research. BMJ 2004;329
doi:10.1136/bmj.329.7460.0.
22 Oxman AD, Chalmers I, Sackett DL. A practical guide to informed consent to treatment.
BMJ 2001;323:1464-6.
23 Morrey BF, An KN, Chao EY. Functional evaluation of the elbow. In: Morrey BF, ed. Elbow
and its disorders . WB Saunders, 1993:86-97.
24 Roles NC, Maudsley RH. Radial tunnel syndrome: resistant tennis elbow as a nerve
entrapment. J Bone Joint Surg Br 1972;54:499-508.
25 Gabler NB, Duan N, Vohra S, Kravitz RL. N-of-1 trials in the medical literature: a systematic
review. Med Care 2011;49:761-8.
26 Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Deciding on the best therapy. In: Clinical
epidemiology: a basic science for clinical medicine . 2nd ed. Little Brown, 1991: 187-248.
27 Backman CL, Harris SR. Case studies, single-subject research, and N of 1 randomized
trials: comparisons and contrasts. Am J Phys Med Rehabil 1999;78:170-6.
28 Shakespeare W. Hamlet I. v. 920.
29 Smith R. The ethics of N of 1 trials in routine practice and other problems of publication
ethics. Cases J 2008;1:78.
30 Shakespeare W. Measure for measure V. i. 2835.
31 Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give
population comparative treatment effect estimates: methodologic considerations. J Clin
Epidemiol 2010;63:1312-23.
32 Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Outcomes
of patients who participate in randomised controlled trials compared to similar patients
receiving similar interventions who do not participate. Cochrane Database Syst Rev
2007;(2):MR000009.
Cite this as: BMJ 2011;343:d7653
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d7653 doi: 10.1136/bmj.d7653 (Published 20 December 2011) Page 3 of 5
RESEARCHWhat is already known on this topic
Single self experiments are common in all fields of medicine except clinical epidemiology
There are more things in heaven and earth than are dreamt of in your clinical epidemiology handbook
What this study adds
An example of self experimentation in clinical epidemiology
A novel study design
Not much else
Table
Table 1| Baseline and follow-up measures of elbow pain and function in control (right) and treated (left) arms
Difference left−right Left arm Right arm
Baseline:
39 67 28 VAS score*
17 48.5 31.5 PRTEE scale†
−22.5 30 52.5 Mayo score‡
0 4 4 Roles-Maudsley score§
1 month follow-up:
40 65 25 VAS score*
14 42.5 28.5 PRTEE scale†
−22.5 35 57.5 Mayo score‡
1 4 3 Roles-Maudsley score§
3 month follow-up:
21 34 13 VAS score*
8 19.5 11.5 PRTEE scale†
−5 77.5 82.5 Mayo score‡
1 2 1 Roles-Maudsley score§
6 month follow-up:
6.5 10.5 4 VAS score*
5.5 10.5 5 PRTEE scale†
−7.5 80 87.5 Mayo score‡
1 2 1 Roles-Maudsley score§
Difference 6 months−baseline:
−32.5 −56.5 −24 VAS score*
−11.5 −38 −26.5 PRTEE scale†
15 50 35 Mayo score‡
1 −2 −3 Roles-Maudsley score§
*VAS=visual analogue scale, median value of twice daily measurements over 7 days (n=14).
†PRTEE=patient rated tennis elbow evaluation scale.
18
‡Mayo functional elbow score.
23
§Roles-Maudsley score.
24
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RESEARCHFigures
Fig 1 Magnetic resonance imaging (turbo spin echo, fat saturated, proton density weighted) of the patient’s left elbow in
coronal (A) and transverse (B) views. Images show signal hyperintensity in the medial epicondyle and lateral osteophytes
of the olecranon, and severe skin atrophy (arrow). (Translation into English: it is very painful)
Fig 2 Median (interquartile range) measures of elbow pain on visual analogue scale (VAS) for the right (control) and left
(treated) arms in the first six months from treatment
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d7653 doi: 10.1136/bmj.d7653 (Published 20 December 2011) Page 5 of 5
RESEARCH